Munich-DE
Munich-DE-MOBILE

Transthyretin Amyloidosis (ATTR)

European Society of Cardiology (ESC) 2026

Congress Details

calander28-31 August, 2026 | Germany

locationMunich, Germany

The materials in this section are intended for UK healthcare professionals and include scientific and educational congress content related to vutrisiran▼ and patisiran. The information contained in these presentations and posters was accurate at the time of presentation. Healthcare professionals should consult the current full Prescribing Information [for the most up-to-date information on indications, dosing, contraindications, warnings, and adverse reactions].

Oral

Agenda

RNAiscience.co_.uk-ESC-2026-Amylo'ExTTRa-manifestations-in-FR-pts-with-ATTR-CM-POSTER
icon Presentation Type
Oral Presentation
location icon Location
Munich, Germany
icon Title
Amylo'ExTTRa: Exploring extra-cardiac manifestations in patients with ATTR-CM using a French National Health Data System
RNAiscience.co.uk - ESC 2026- Vutri & preservation of intrinsic capacity and healthy ageing POSTER
icon Presentation Type
Oral Presentation
location icon Location
Munich, Germany
icon Title
Vutrisiran is associated with preservation of intrinsic capacity and healthy ageing in patients with transthyretin amyloidosis with cardiomyopathy: Post hoc analysis of HELIOS-B
mic Presenter

Olivier Lairez

Toulouse University Hospital
Tolouse, France

RNAiscience.co.uk - ESC 2026- Fewer adverse events in ATTR-CM pts treated with AMV vs placebo POSTER
icon Presentation Type
Moderated Poster
location icon Location
Munich, Germany
icon Title
Fewer adverse events reported in ATTR-CM patients treated with vutrisiran versus placebo: post hoc safety analysis from HELIOS-B
mic Presenter

Stéphanie Schwarting

Ludwig Maximillian University of Munich
Munich, Germany

RNAiscience.co.uk - ESC 2026- Effect of Vutrisiran According to Baseline Tafamidis Use POSTER
icon Presentation Type
Oral presentation
location icon Location
Munich, Germany
icon Title
Effect of Vutrisiran According to Baseline Tafamidis Use in Transthyretin Amyloidosis with Cardiomyopathy: Insights from HELIOS-B
RNAiscience.co.uk - ESC 2026- Effect of Vutrisiran According to Baseline Tafamidis Use POSTER
icon Presentation Type
Oral presentation
location icon Location
Munich, Germany
icon Title
Cardiac presentation and treatment response by sex in patients with transthyretin amyloidosis: pooled analysis of vutrisiran and patisiran Phase 3 studies

Associated Materials

European Society of Cardiology (ESC) 2025 Congress, Spain

Transthyretin Amyloidosis (ATTR)

European Society of Cardiology (ESC) 2025

29 August - 1 September 2025 SPAIN

View Details
Preparation Date
March 2026
Job Code
MB-UK-00118

Transthyretin Amyloidosis (ATTR)

Realising the therapeutic potential of rapid knockdown of transthyretin via RNA interference in transthyretin amyloidosis

Molecular Therapy Nucleic Acids

Author(s)

Martha Grogan, Farooq H. Sheikh, Brett W. Sperry

June 2025

Preparation Date
March 2026
Job Code
MB-UK-00168
Heart Failure Association (HFA) 2025 Congress, Serbia

Transthyretin Amyloidosis (ATTR)

Heart Failure Association (HFA) 2025

17-20 May 2025 Serbia

View Details
Preparation Date
March 2026
Job Code
MB-UK-00127
Peripheral Nerve Society (PNS) 2025 Congress, UK

Transthyretin Amyloidosis (ATTR)

Peripheral Nerve Society (PNS) 2025

17-20 May 2025 UK

View Details
Preparation Date
March 2026
Job Code
MB-UK-00130

Transthyretin Amyloidosis (ATTR)

Treatment with vutrisiran in individuals with transthyretin amyloidosis with cardiomyopathy: A plain language summary

Future Cardiology

Author(s)

Marianna Fontana, Julian D Gillmore, Ronald M Witteles

May 2025

Preparation Date
March 2026
Job Code
MB-UK-00169

Transthyretin Amyloidosis (ATTR)

Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B

Journal of the American College of Cardiology

Author(s)

Ronald Witteles, Pablo Garcia-Pavia, Thibaud Damy

May 2025

Preparation Date
March 2026
Job Code
MB-UK-00170
Preparation Date
August 2026
Job Code
MB-UK-00230